An investigation on behalf of investors of BeiGene, Ltd. (NASDAQ: BGNE) shares over potential securities laws violations by BeiGene, Ltd. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of BeiGene, Ltd. (NASDAQ: BGNE) concerning whether a series of statements by BeiGene, Ltd. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

China based BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationaly.

On September 5, 2019, a report was published concerning BeiGene, Ltd. The report asserted, inter alia, that BeiGene is faking sales in order to persuade investors that it can develop a successful platform in China and that management may also be skimming R&D and capital budgets.